iCardiac Launches Wide-Scope Safety Study


The late phase respiratory and cardiac safety study will involve 14,000 patients across 750 sites, the company's largest such trial in its history.

iCardiac, a core laboratory for cardiac safety and respiratory services, has begun enrolling patients in the company's largest-ever late phase respiratory and cardiac safety study. The three-year trial will be conducted at sites in 28 countries and will include about 340,000 pulmonary function tests and 90,000 ECG reviews, according to iCardiac.

In July 2015, the company acquired the clinical trials division of nSpire Health (read background on the deal here).   

Read the full release

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.